Objective: To analyze the clinical features of pandrug-resistant Acinetobacter baumannii (PDR-Ab) in the Chinese PLA General Hospital and compare the efficacies of different antibiotic treatments in aged patients with ventilator-associative pneumonia (VAP) caused by PDR-Ab.
Methods: Data were collected from all isolated PDR-Ab strains in our hospital from April 2009 to April 2010. The clinical features, treatment, and outcomes were retrospectively reviewed.
Results: PDR-Ab was found to be the dominant pathogen in 42 of 126 aged VAP patients. Cefoperazone/sulbactam plus minocycline showed good efficacy in 20 patients with PDR-Ab VAP, showing a clinical cure rate of 65% (13/20) and a bacterial eradication rate of 40% (8/20). Another 22 patients were treated with other antimicrobial drugs, achieving a clinical cure rate of 22.7% (5/22) and a bacterial eradication rate of 13.6% (3/22). The factors influencing bacterial clearance were prolonged length of hospital stay and mechanical ventilation prior to positive culture (all P<0.01).
Conclusion: Cefoperazone/sulbactam plus minocycline can be an effective treatment for VAP caused by PDR-Ab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3881/j.issn.1000-503X.2014.02.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymyxin-B induced Bartter-like syndrome: an unusual adverse effect.
Ann Med Surg (Lond)
December 2024
Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh.
Introduction And Importance: Bartter syndrome is a rare autosomal recessive disorder affecting renal tubular function leading to disturbances in electrolyte and volume homeostasis. It can also manifest as Bartter-like syndrome (BLS), a rare side effect of certain medications. Polymyxin-B, an antibiotic used to treat multidrug-resistant infections is infrequently associated with BLS.
View Article and Find Full Text PDFMolecular typing of reduced susceptibility of complex to Chlorhexidine in Turkey by pulsed-field gel electrophoresis.
J Med Microbiol
August 2024
Medical Microbiology Department, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
. The global spread of spp., particularly the (ACB) complex, has led to its recognition as a significant pathogen by the World Health Organization (WHO).
View Article and Find Full Text PDFCombinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Patient Isolates.
Microorganisms
July 2024
Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
Infections due to drug-resistant strains are increasing and cause significant morbidity and mortality, especially in hospitalized and critically ill patients. rapidly develops resistance to numerous antibiotics, and antibiotics traditionally used against this deadly pathogen have been failing in recent years, highlighting the need to identify new treatment strategies. Treatment options that have shown promise include revisiting common antibiotics not typically used against , evaluating new antibiotics recently introduced to market, and identifying combinations of antibiotics that display synergistic interactions.
View Article and Find Full Text PDF: the emergence of a hospital-acquired pathogen analyzed from the genomic perspective.
Front Microbiol
June 2024
Universidad Nacional Autónoma de México, Centro de Ciencias Genómicas, Programa de Genómica Evolutiva, Cuernavaca, Mexico.
Article Synopsis
- Hospital-acquired severe infections are linked to genetic factors related to antibiotic resistance, specifically in strains that may carry genes for carbapenem and tigecycline resistance.
- A study analyzed 384 genomes from clinical and non-clinical sources globally, revealing significant variability in genetic content, with antibiotic resistance genes largely found in the accessory genome.
- The research indicates that while core genomes of environmental and hospital isolates are similar, the hospital strains acquire antibiotic resistance genes due to high selective pressure, with no geographical bias in their distribution.
The Evolving Challenge of Appropriate Antibiotics Use in Hospitalized COVID-19 Patients: A Systematic Literature Review.
Antibiotics (Basel)
June 2024
Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy.
The issue of bacterial infections in COVID-19 patients has received increasing attention. Scant data are available on the impact of bacterial superinfection and antibiotic administration on the outcome of hospitalized COVID-19 patients. We conducted a literature review from 1 January 2022 to 31 March 2024 to assess the current burden of bacterial infection and the evidence for antibiotic use in hospitalized COVID-19 patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!